Skip to main content
SpringerLink
Log in

Use topical or oral agents to treat fungal infections of the feet in diabetic patients

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Tan JS, Joseph WS. Common fungal infections of the feet in patients with diabetes mellitus. Drugs Aging 2004; 21(2): 101–12

    Article  PubMed  CAS  Google Scholar 

  2. Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998; 139(4): 665–71

    Article  PubMed  CAS  Google Scholar 

  3. Gupta AK, Cooper EA, Ryder JE, et al. Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol 2004; 5(4): 225–37

    Article  PubMed  Google Scholar 

  4. British National Formulary No. 48 [online]. Available from URL: http://www.bnf.org [Accessed 2004 Oct 22]

  5. Bell-Syer SE, Hart R, Crawford F, et al. A systematic review of oral treatments for fungal infections of the skin of the feet. J Dermatolog Treat 2001; 12: 69–74

    Article  PubMed  CAS  Google Scholar 

  6. Abu-Aliat SA, Howell SA, Moore MK, et al. The microbial flora of toenails in diabetes mellitus [abstract no. P-48]. Br J Dermatol 2003; 149Suppl. 64: 38

    Google Scholar 

  7. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev 1998; 11(3): 415–29

    PubMed  CAS  Google Scholar 

  8. Seebacher C, Nietsch KH, Ulbricht HM. A multicenter, open-label study of the efficacy and safety of ciclopirox nail laquer solution 8% for the treatment of onychomycosis in patients with diabetes. Cutis 2001; 68(2 Suppl.): 17–22

    PubMed  CAS  Google Scholar 

  9. Crawford F, Young P, Godfrey C, et al. Oral treatments for toenail onychomycosis: a systematic review. Arch Dermatol 2002; 138(6): 811–6

    Article  PubMed  CAS  Google Scholar 

  10. Farkas B, Paul C, Dobozy A, et al. Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol 2002; 146(2): 254–60

    Article  PubMed  CAS  Google Scholar 

  11. Gupta AK, Konnikov N, Lynde CW. Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J Am Acad Dermatol 2001; 44(3): 479–84

    Article  PubMed  CAS  Google Scholar 

  12. Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ 1999; 318: 1031–5

    Article  PubMed  CAS  Google Scholar 

  13. Vander Straten MR, Hossain MA, Ghannoum MA. Cutaneous infections, dermatophytosis, onychomycosis, and tinea versicolor. Infect Dis Clin North Am 2003; 17: 87–112

    Article  Google Scholar 

  14. Havu V, Heikkila H, Kuokkanen K, et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol 2000; 142: 97–102

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Use topical or oral agents to treat fungal infections of the feet in diabetic patients. Drugs Ther. Perspect 21, 20–23 (2005). https://doi.org/10.2165/00042310-200521020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200521020-00006

Search

Navigation